BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11961071)

  • 1. Agonist, antagonist, and inverse agonist characteristics of TIPP (H-Tyr-Tic-Phe-Phe-OH), a selective delta-opioid receptor ligand.
    Martin NA; Ruckle MB; VanHoof SL; Prather PL
    J Pharmacol Exp Ther; 2002 May; 301(2):661-71. PubMed ID: 11961071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agonist Activity of the delta-antagonists TIPP and TIPP-psi in cellular models expressing endogenous or transfected delta-opioid receptors.
    Martin NA; Terruso MT; Prather PL
    J Pharmacol Exp Ther; 2001 Jul; 298(1):240-8. PubMed ID: 11408548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delta opioid modulation of the binding of guanosine-5'-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects.
    Szekeres PG; Traynor JR
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1276-84. PubMed ID: 9400003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid receptor binding characteristics and structure-activity studies of novel tetrapeptides in the TIPP (Tyr-Tic-Phe-Phe) series.
    Ioja E; Tóth G; Benyhe S; Tourwe D; Péter A; Tömböly C; Borsodi A
    Neurosignals; 2005; 14(6):317-28. PubMed ID: 16772734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive study on the putative δ-opioid receptor (sub)types using the highly selective δ-antagonist, Tyr-Tic-(2S,3R)-β-MePhe-Phe-OH.
    Birkas E; Bakota L; Gulya K; Wen T; Pintar J; Tóth G; Szucs M
    Neurochem Int; 2011 Aug; 59(2):192-201. PubMed ID: 21672586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine-iodination converts the delta-opioid peptide antagonist TIPP to an agonist.
    Lee PH; Nguyen TM; Chung NN; Schiller PW; Chang KJ
    Eur J Pharmacol; 1995 Jul; 280(2):211-4. PubMed ID: 7589188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal guanidinylation of TIPP (Tyr-Tic-Phe-Phe) peptides results in major changes of the opioid activity profile.
    Weltrowska G; Nguyen TM; Chung NN; Wilkes BC; Schiller PW
    Bioorg Med Chem Lett; 2013 Sep; 23(18):5082-5. PubMed ID: 23932788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
    Liu JG; Prather PL
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists.
    Schiller PW; Weltrowska G; Berezowska I; Nguyen TM; Wilkes BC; Lemieux C; Chung NN
    Biopolymers; 1999; 51(6):411-25. PubMed ID: 10797230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of inverse agonism at the delta opioid receptor after expression in Rat 1 fibroblasts.
    Mullaney I; Carr IC; Milligan G
    Biochem J; 1996 Apr; 315 ( Pt 1)(Pt 1):227-34. PubMed ID: 8670111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reciprocal regulation of agonist and inverse agonist signaling efficacy upon short-term treatment of the human delta-opioid receptor with an inverse agonist.
    Piñeyro G; Azzi M; deLéan A; Schiller PW; Bouvier M
    Mol Pharmacol; 2005 Jan; 67(1):336-48. PubMed ID: 15496503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Src in ligand-specific regulation of delta-opioid receptor desensitization and internalization.
    Hong MH; Xu C; Wang YJ; Ji JL; Tao YM; Xu XJ; Chen J; Xie X; Chi ZQ; Liu JG
    J Neurochem; 2009 Jan; 108(1):102-14. PubMed ID: 19014372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel TIPP (H-Tyr-Tic-Phe-Phe-OH) analogues displaying a wide range of efficacies at the δ opioid receptor. Discovery of two highly potent and selective δ opioid agonists.
    Berezowska I; Lemieux C; Chung NN; Ding J; Schiller PW
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1899-902. PubMed ID: 22325949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of isothiocyanate-containing derivatives of the delta-opioid receptor antagonist Tyr-Tic-Phe-Phe (TIPP) as potential affinity labels for delta-opioid receptors.
    Maeda DY; Berman F; Murray TF; Aldrich JV
    J Med Chem; 2000 Dec; 43(26):5044-9. PubMed ID: 11150176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile.
    Tourwé D; Mannekens E; Diem TN; Verheyden P; Jaspers H; Tóth G; Péter A; Kertész I; Török G; Chung NN; Schiller PW
    J Med Chem; 1998 Dec; 41(26):5167-76. PubMed ID: 9857087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TIPP[psi]: a highly potent and stable pseudopeptide delta opioid receptor antagonist with extraordinary delta selectivity.
    Schiller PW; Weltrowska G; Nguyen TM; Wilkes BC; Chung NN; Lemieux C
    J Med Chem; 1993 Oct; 36(21):3182-7. PubMed ID: 8230106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a model for the delta-opioid receptor pharmacophore: 3. Comparison of the cyclic tetrapeptide, Tyr-c[D-Cys-Phe-D-Pen]OH with other conformationally constrained delta-receptor selective ligands.
    Lomize AL; Pogozheva ID; Mosberg HI
    Biopolymers; 1996 Feb; 38(2):221-34. PubMed ID: 8589255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Aladan3]TIPP: a fluorescent delta-opioid antagonist with high delta-receptor binding affinity and delta selectivity.
    Chen H; Chung NN; Lemieux C; Zelent B; Vanderkooi JM; Gryczynski I; Wilkes BC; Schiller PW
    Biopolymers; 2005; 80(2-3):325-31. PubMed ID: 15614807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inverse agonism and neutral antagonism at wild-type and constitutively active mutant delta opioid receptors.
    Tryoen-Tóth P; Décaillot FM; Filliol D; Befort K; Lazarus LH; Schiller PW; Schmidhammer H; Kieffer BL
    J Pharmacol Exp Ther; 2005 Apr; 313(1):410-21. PubMed ID: 15590769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.